login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
FIBROGEN INC (FGEN) Stock News
NASDAQ:FGEN -
US31572Q8087
-
Common Stock
11.13
USD
-0.7 (-5.92%)
Last: 9/2/2025, 11:29:10 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FGEN Latest News, Press Relases and Analysis
All
Press Releases
5 hours ago - By: FibroGen, Inc.
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
6 days ago - By: FibroGen, Inc.
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
15 days ago - By: FibroGen, Inc.
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
21 days ago - By: Benzinga
- Mentions:
PRPH
AZTR
MYO
TLRY
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
22 days ago - By: Zacks Investment Research
- Mentions:
AIM
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
25 days ago - By: Benzinga
Uncovering Potential: FibroGen's Earnings Preview
22 days ago - By: FibroGen, Inc.
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
a month ago - By: FibroGen, Inc.
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
a month ago - By: FibroGen, Inc.
FibroGen to Report Second Quarter 2025 Financial Results
2 months ago - By: The Motley Fool
- Mentions:
VRTX
PROK
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
3 months ago - By: FibroGen, Inc.
FibroGen Announces 1-for-25 Reverse Stock Split
3 months ago - By: FibroGen, Inc.
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
4 months ago - By: Zacks Investment Research
- Mentions:
MDWD
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
4 months ago - By: FibroGen, Inc.
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Zacks Investment Research
- Mentions:
STVN
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
4 months ago - By: FibroGen, Inc.
FibroGen to Report First Quarter 2025 Financial Results
5 months ago - By: FibroGen, Inc.
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
5 months ago - By: FibroGen, Inc.
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
6 months ago - By: FibroGen, Inc.
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
6 months ago - By: FibroGen, Inc.
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Please enable JavaScript to continue using this application.